Pixantrone

BNF:

8.1.2

Status:

Red

Decision Date:

March 2014

Comments

RED:^1,2,3 NICE TA306: Monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkins B-cell lymphoma

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again